### **Overview** Kerala Ayurveda Limited (KAL) is one of the world’s oldest and most respected **full-spectrum Ayurveda companies**, with a heritage spanning over **80 years** rooted in traditional Kerala Ayurveda and Yoga. Publicly listed on the Bombay Stock Exchange (BSE), KAL operates globally across six integrated verticals: - **Products** - **Wellness Resorts (Ayurvedagram)** - **Hospitals & Clinics** - **Academies (Education)** - **Digital Commerce (D2C & B2B)** - **Services** With a physical and digital presence in **India, the USA, Singapore, and Indonesia**, the company serves over **100,000 patients annually**, has trained **over 3,500 graduates** globally, and offers **400+ Ayurvedic SKUs**. --- ### **Recent Financial Performance (Consolidated)** - **FY 2023–24 Revenue**: ₹11,307 lakhs (**INR 1,130.7 crores**), a **21% YoY growth** from FY23. - **EBITDA**: ₹708 lakhs, up **179% YoY**, reflecting improved operational efficiency. - **Q1 FY26 (Apr–Jun 2025) Revenue**: ₹3,045 lakhs, an **18.4% YoY increase**. - **Q1 FY26 PAT**: ₹2.03 crores, despite heavy investments in talent and infrastructure. - **FY 2022–23 Revenue**: ₹937 crores, with **30% YoY growth in FY21–22**, demonstrating strong pandemic recovery. The company reported a **loss in FY25**, attributed to **strategic investments** in talent, infrastructure, digital platforms, and ESOPs totaling over ₹800 crores. --- ### **Growth Strategy & Strategic Initiatives (FY25–FY26)** #### **1. Aggressive Topline Expansion** KAL aims to **double its topline to ₹7,185 crores by FY26**, representing a **~50% growth** from FY25, supported by: - **Digital-first growth** in Direct-to-Consumer (D2C) channels: - Target **2x growth in India D2C**, **3x growth in the U.S.** market. - Leverage **AI-driven personalized wellness recommendations**. - Expansion of **digital footprint** via partnerships with Flipkart, Nykaa, 1mg, and Amazon. - Entry into **e-pharmacy and quick commerce**. #### **2. Expansion of Health Services** - **Ayurvedagram Wellness Retreats**: - **Bengaluru center**: Achieved **record 90% occupancy**. - **Bali, Indonesia**: Achieved **71% revenue growth in FY25**; second property underway. - The Bali joint venture is being **fully consolidated** into KAL’s financials, expected to add **₹20 crores in incremental revenue**. - **KALPAM (phygital partnership model)**: Enables Ayurvedic doctors to open branded clinics and franchises under KAL’s banner, supported by supply chain and digital enablement. - Launch of **20 new day clinics in India** (2 already operational), with record clinic openings planned for FY25–26. #### **3. Product Innovation & Brand Revamp** - **"Ru by Kerala Ayurveda"** (FY26 Launch): - A **premium consumer brand** targeting modern, health-conscious audiences. - Focus: **purity, potency, elegance, and cellular rejuvenation**. - **"KERALA AYURVEDA inside" Initiative**: - New line of **scientifically validated premium products** with unmatched claims on **safety and efficacy**. - Supported by third-party clinical studies. - Pipeline of **40+ new products**, including **OTC, skincare, and nutraceuticals**, targeting ailments with limited allopathic solutions. #### **4. Scientific Validation & Intellectual Property** - **U.S. Patent Grant**: For a proprietary herbal formulation targeting **metabolic syndrome** (diabetes, obesity, lipid imbalance). - Validated by **preclinical studies (USA)** and **double-blind, placebo-controlled clinical trial at BHU (India)**, under USFDA standards. - First-ever **U.S. patent for an Ayurvedic formulation**, marking a global milestone. - Additional patents pending in **Japan and the U.S.** - Strong R&D infrastructure: DST-DSIR recognized center; collaboration with **Renovel Discoveries (USA)** and **Asthagiri Herbal Research Foundation (India)**. --- ### **International Expansion & Global Presence** - **USA**: - **Kerala Ayurveda Academy (California & Washington)**: Over **3,500 trained professionals**, offering **6,000+ hours of state-certified courses**. - New **educational modules** in *Marma*, beauty, and "Hero" entry-level programs to boost enrollment. - U.S. revenue in FY23: ₹218 crores; U.S. e-commerce grew 34% in FY24. - **Singapore & GCC Markets**: Expansion via **OmVeda and Nutraveda** partnerships. - **Europe**: Exploring entry through e-commerce and B2B alliances. --- ### **Investments & Infrastructure (2024–2025)** KAL is undergoing a transformation via **"KAL 2.0"** — a strategic phase integrating **Ayurveda with modern science, digitalization, and global scalability**. Key investments include: - **₹713.5 crores** in **talent acquisition** (digital, innovation, clinical, education). - **₹76 crores** in **digital marketing**, achieving **7x increase in digital reach**. - **₹6 crores** in infrastructure: - Upgrading **Ayurvedagram luxury rooms**, **clinic modernization**, and **production equipment modernization**. - Investment in **CRM integration** to leverage **hundreds of thousands of loyal customers** in a digitally enabled ecosystem. --- ### **Key Leadership & Governance** - **Dr. K. Anilkumar (Executive Director)**: - Elder son of founder **Vaidyan KGK Panicker**, with **40+ years of experience**. - Instrumental in transforming the family business into a **publicly listed, full-spectrum Ayurveda leader**. - **Vivek Sunder (CEO & President, since Oct 2023)**: - Former executive at **P&G and Swiggy**, bringing modern corporate and digital strategy. - Focused on **U.S. growth, global digitization, and doctor-centric distribution reform**. --- ### **Operational Model & Competitive Edge** - **Phygital (Physical + Digital) Strategy**: - Hybrid model combining **on-ground wellness experiences** with **digital health, e-commerce, and teleconsultations**. - **Full-Stack Ayurveda Advantage**: - Unlike pure-play product startups, KAL integrates **education, clinical outcomes, product R&D, and services**, creating a **vertically integrated ecosystem**. - **Quality Leadership**: - GMP-compliant manufacturing, **traceable sourcing**, and **standardized batch processes**. - Over **148 U.S. products comply with California Prop 65 and USFDA standards**.